$97 Million

La Jolla Pharmaceutical

Follow-on Offering

Bookrunner, September 2015

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company’s lead product candidate, LJPC-501, is a proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH) and recently announced Phase 3 data. The Company recently announced LJPC-501 Phase 3 data with the achievement of the primary endpoint and further positive top-line results including a 22% reduction in mortality rate at day 28 and improvements in safety and tolerability over the placebo-treated patients. La Jolla plans to submit a NDA for LJPC-501 in 2H 2017 with FDA approval expected in 2H 2018.